SKN | Could J&J’s New Psoriasis Pill Disrupt the $100 Billion Biologics Market?
Uncategorized The approval of a new oral treatment by Johnson & Johnson marks a potentially pivotal shift in the treatment landscape for autoimmune diseases. The U.S. Food and Drug Administration has cleared Icotyde, a once-daily pill for moderate to severe plaque psoriasis, positioning it as a direct competitor to blockbuster injectable biologics. The move comes as […]